Skip to content

Cytek Biosciences, Inc. CTKB Ratios & Valuation

TTM Q1 '26TTM Q4 '25TTM Q3 '25TTM Q2 '25TTM Q1 '25
Profitability
Gross margin51.7%-0.1pp51.8%-1.6pp53.5%-1.0pp54.4%-0.5pp54.9%-0.5pp
Efficiency
Asset turnover0.4×0.0×0.4×0.0×0.4×0.0×0.4×0.0×0.4×0.0×
Liquidity
Current ratio4.7×-0.4×-0.1×5.2×-0.1×5.2×-0.4×5.6×-0.2×
Leverage
Debt-to-equity0.1×0.0×0.1×0.0×0.0×0.0×0.0×
Per Share
Book value per share$2.55-4.8%$2.68-9.9%$2.97-0.2%$2.97+0.6%$2.96-2.4%
Valuation
Market capitalization$577.27M+54.5%$645.72M+46.3%$441.47M+7.9%$409.11M-20.4%$513.67M-38.6%
Price / sales2.8×+0.9×3.2×+1.0×2.2×+0.2×2.1×-0.5×2.6×-1.6×
Price / book1.8×+0.8×1.9×+0.7×1.2×+0.1×1.1×-0.3×1.4×-0.8×

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

What are Cytek Biosciences, Inc.'s profit margins?
Cytek Biosciences, Inc. (CTKB) runs a 51.7% gross margin and a -21.5% operating margin, with a -36.2% net margin.
Where do Cytek Biosciences, Inc.'s ratios come from?
Every ratio is computed from Cytek Biosciences, Inc.'s SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.